McKesson in the news
Healthcare solutions and services
Tamtam found 19 recent articles about McKesson.
- McKesson, CD&R to Acquire Option Care Health
McKesson and Clayton, Dubilier & Rice agreed to acquire Option Care Health for approximately $5.8 billion, enhancing McKesson's focus on specialty therapies and infusion care.
- Option Care Stock Trades Below McKesson's Deal Price — Here's the Spread
McKesson is investing $1.4 billion for a 49% stake in Option Care Health, aiming to expand access to innovative therapies, with the deal expected to close in the first half of 2027.
- McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports
McKesson and private equity firm CD&R are nearing a deal to acquire infusion services provider Option Care Health for over $5 billion.
- How Distribution Is Evolving for Today's Targeted Therapies
McKesson's Chris Van Norman is discussing distribution evolution for targeted therapies at LogiPharma USA, focusing on demand signal sharing and AI.
- McKesson Eyes Option Care Deal With CD&R
McKesson and Clayton Dubilier & Rice are reportedly close to acquiring Option Care Health for over $5 billion, advancing McKesson's move into broader healthcare services.
- Option Care Jumps on Report McKesson Is Preparing an Offer
Option Care Health's shares rose on news that McKesson and Clayton Dubilier & Rice are reportedly close to making a $5 billion-plus offer to acquire the medical infusion company.
- McKesson and CD&R near $5bn-plus deal to buy infusion services provider
McKesson and CD&R are in advanced talks to acquire Option Care Health, a major medical infusion services provider, for over $5 billion.
- McKesson stock extends CVS pact through 2032 with guidance intact
McKesson secured a contract extension with CVS Health until 2032 and reaffirmed its fiscal 2027 adjusted EPS guidance.
- Wall Street Gains on Payroll Data; McKesson (MCK) Outperforms He
McKesson (MCK) outperformed the declining healthcare sector with a 4.11% gain on Wall Street's positive reaction to weak payroll data, despite being modestly overvalued according to GF Value™.
- McKesson stock trades at USD 902.28 after CVS deal
McKesson stock is trading at USD 902.28 after a new distribution agreement with CVS, while exceeding Q1 fiscal 2027 revenue and adjusted EPS estimates and reaffirming future guidance.
- Cardinal Health, McKesson Extend CVS Distribution Deals to 2032
Cardinal Health and McKesson extended their distribution contracts with CVS until 2032.
- McKesson rises as investors lean on strong earnings momentum and strategic deal activity
McKesson's stock increased following strong Q1 FY27 earnings, raised full-year guidance, and the acquisition of Precision Medicine Group.
- MCK News Today | Why did McKesson stock go up today? $MCK
McKesson stock increased following an extended pharmaceutical distribution partnership with CVS Health and reaffirmed fiscal 2027 earnings guidance.
- Why McKesson Stock Soared More Than 5% Higher Today
McKesson's stock increased by over 5% following the announcement of an extended pharmaceutical distribution partnership with CVS Health until June 2032.
- Why McKesson (MCK) Stock Is Trading Up Today
McKesson's stock rose 4.4% today after extending its pharmaceutical distribution partnership with CVS Health until June 2032.
- McKesson extends CVS deal; shares rise
McKesson extended its pharmaceutical distribution agreement with CVS Health until June 2032, causing its shares to rise.
- Mckesson Corp Stock (MCK) Moved Up by 4.52% on Oct 1: What Investors Need To Know
McKesson's stock rose 4.52% after extending its pharmaceutical distribution contract with CVS Health until June 2032, securing long-term revenue.
- McKesson Extends CVS Pharmaceutical Distribution Agreement Through 2032
McKesson extended its pharmaceutical distribution agreement with CVS Health until June 2032, covering various pharmacy channels and ensuring business continuity.
- McKesson Corp (MCK) Stock Up 5.3% but GF Value Says Overvalued -- GF Score: 86/100
McKesson Corp shares increased by 5.3% to $898.82 on October 1, 2026, despite being considered overvalued by 7.8% based on the GF Value™.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like McKesson?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies